936361-36-3

Basic information

• Product Name: 3,8-Dibromoimidazo[1,2-a]pyrazine
• Synonyms: 3,8-Dibromoimidazo[1,2-a]pyrazine
• CAS NO: 936361-36-3
• Molecular Formula: C₆H₃Br₂N₃
• Molecular Weight: 276.91612
• Mol File: 936361-36-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,8-Dibromoimidazo[1,2-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,8-Dibromoimidazo[1,2-a]pyrazine(936361-36-3)
• EPA Substance Registry System: 3,8-Dibromoimidazo[1,2-a]pyrazine(936361-36-3)

Safety Data

• Hazardous Substances Data: 936361-36-3(Hazardous Substances Data)

Upstream product

• 69214-33-1 8-chloroimidazo[1,2-α]pyrazine 
• 274-79-3 imidazo[1,2-a]pyrazine 

Downstream Products

• 1011472-09-5 3-bromo-N-phenylimidazo[1,2-a]pyrazin-8-amine 
• 1231257-91-2 3-bromo-N-cyclohexylimidazo[1,2-a]pyrazin-8-amine 
• 887475-39-0 3-bromo-8-methylsulfanyl-imidazo[1,2-a]pyrazine 
• 1231257-89-8 3-bromo-8-((3-(trifluoromethyl)phenyl)amino)imidazo[1,2-a]pyrazine 
• 887474-76-2 C₁₄H₁₄BrN₅ 
• 117718-92-0 8-amino-3-bromoimidazo<1,2-a>pyrazine 
• 787590-51-6 (3-bromo-imidazo[1,2-a]pyrazin-8-yl)-(4-methoxy-phenyl)-amine 

Relevant articles and documents

IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Compounds of formula (I): wherein R1, R2, X1, and X2 are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.

Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors

The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.